Combined treatment of uterine leiomyosarcoma with gamma secretase inhibitor MK-0752 and chemotherapeutic agents de-creases cellular invasion and increases apoptosis
RNA-seq (gene expression) · human · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 12 samples: 6 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Combined Treatment of Uterine Leiomyosarcoma with Gamma Secretase Inhibitor MK-0752 and Chemotherapeutic Agents Decreases Cellular Invasion and Increases ApoptosisCancers · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE268019_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1114061 and SRA study SRP511694. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 6 replicated groups read from 12 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8283997 SKLMS1-DMSO-2-1 SKLMS1-DMSO-2
- GSM8283998 SKLMS1-DMSO-2-3 SKLMS1-DMSO-2
- GSM8283999 SKLMS1-DMSO-4-1 SKLMS1-DMSO-4
- GSM8284000 SKLMS1-DMSO-4-2 SKLMS1-DMSO-4
- GSM8284001 SKLMS1-MGD-4-1 SKLMS1-MGD-4
- GSM8284002 SKLMS1-MGD-4-2 SKLMS1-MGD-4
- GSM8284003 SKLMS1-MK-2-2 SKLMS1-MK-2
- GSM8284004 SKLMS1-MK-2-3 SKLMS1-MK-2
- GSM8284005 SKUT1B-DMSO-4-1 SKUT1B-DMSO-4
- GSM8284006 SKUT1B-DMSO-4-2 SKUT1B-DMSO-4
- GSM8284007 SKUT1B-MGD-3-1 SKUT1B-MGD-3
- GSM8284008 SKUT1B-MGD-3-3 SKUT1B-MGD-3
- GSE324741 Detection of transcriptomic changes in N9 and N33 GBM cells following treatment with small molecular inhibitors of MK-0752, WP1066 and retinoic acid 18 samples shares mk-0752, treatment, inhibitor
- GSE275087 Next-Generation Sequencing Facilitates Quantitative Analysis of Control and BET bromodomain Inhibitor-treated Uterine Leiomyosarcoma Cell Transcriptome 12 samples shares leiomyosarcoma, inhibitor
- GSE224306 Next-Generation Sequencing Facilitates Quantitative Analysis of Control and FTO Inhibitor-treated Uterine Leiomyosarcoma Cell Transcriptome 8 samples shares leiomyosarcoma, inhibitor
- GSE290747 Hinokiflavone, a novel CK2 inhibitor, promotes apoptosis and synergizes with chemotherapeutic agents in cisplatin-resistant bladder cancer cells. 4 samples shares chemotherapeutic, inhibitor
- GSE297689 Synthetic lethality from the combination of a histone methyltransferase, SUV39H2 inhibitor, and a poly (ADP-ribose) polymerase inhibitor for uterine leiomyosarcoma [RNA-Seq] 2 samples shares leiomyosarcoma, inhibitor
- GSE251999 Next Generation Thiazolyl Ketone Inhibitors of Cytosolic Phospholipase A2 α: from Synthesis to Chemotherapeutic Mechanism of Action 24 samples shares chemotherapeutic, inhibitor
- GSE297686 Synthetic lethality from the combination of a histone methyltransferase, SUV39H2 inhibitor, and a poly (ADP-ribose) polymerase inhibitor for uterine leiomyosarcoma [ChIP-Seq] 4 samples shares leiomyosarcoma, inhibitor
- GSE276695 Chemotherapeutic agents and leucine deprivation induce codon-biased aberrant protein production in cancer 24 samples shares chemotherapeutic
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.